EP0038869A1 - Process for the preparation of 1-carbapenems, and intermediates for their preparation - Google Patents
Process for the preparation of 1-carbapenems, and intermediates for their preparation Download PDFInfo
- Publication number
- EP0038869A1 EP0038869A1 EP80102338A EP80102338A EP0038869A1 EP 0038869 A1 EP0038869 A1 EP 0038869A1 EP 80102338 A EP80102338 A EP 80102338A EP 80102338 A EP80102338 A EP 80102338A EP 0038869 A1 EP0038869 A1 EP 0038869A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- carbon atoms
- alkyl
- phenyl
- substituted
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 *C(*)(C1N2C(C(O*)=O)=C(*)C1)*2O Chemical compound *C(*)(C1N2C(C(O*)=O)=C(*)C1)*2O 0.000 description 19
- SAYVKPQBQLEJFP-UHFFFAOYSA-N CC(C(C(CC=C)NC)C(C)=O)O Chemical compound CC(C(C(CC=C)NC)C(C)=O)O SAYVKPQBQLEJFP-UHFFFAOYSA-N 0.000 description 1
- ZXVOLUDPQJOTMA-UHFFFAOYSA-N CC1=NNNN1C Chemical compound CC1=NNNN1C ZXVOLUDPQJOTMA-UHFFFAOYSA-N 0.000 description 1
- OQUKUGBFUYWUHX-LURJTMIESA-N CCC(C=C=C([C@@H]1C)S)=C1N Chemical compound CCC(C=C=C([C@@H]1C)S)=C1N OQUKUGBFUYWUHX-LURJTMIESA-N 0.000 description 1
- GNFDUDNUYPLTMI-UNFKKNOASA-N OC(C1CC1)[C@@H](C(CC1SCc2ncccc2)N2C1C(O)=O)C2O Chemical compound OC(C1CC1)[C@@H](C(CC1SCc2ncccc2)N2C1C(O)=O)C2O GNFDUDNUYPLTMI-UNFKKNOASA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
- C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
- C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65611—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system (X = CH2, O, S, NH) optionally with an additional double bond and/or substituents, e.g. penicillins and analogs
Definitions
- This invention relates to the total synthesis of certain 1-carbapenems and their pharmaceutically acceptable salt, ester and amide derivatives which are useful as antibiotics.
- Such compounds may generically be represented by the following structural formula: wherein R 6 , R 7 , and R 6 are independently selected from the group consisting of hydrogen, substituted and unsubstituted: alkyl, alkenyl, and alkynyl, having from 1-10 carbon atoms; cycloalkyl, cycloalkylalkyl, and alkylcycloalkyl, having 3-6 carbon atoms in the cycloalkyl ring and 1-6 carbon atoms in the alkyl moieties; aryl, such as phenyl; aralkyl, aralkenyl, and aralkynyl wherein the aryl moiety is phenyl and the aliphatic portion has 1-6 carbon atoms; heteroaryl, heteroaralkyl, heterocyclyl and heterocyclylalkyl
- intermediates III and IV wherein R 6 and R 7 are as previously defined; X is a conventional leaving group and R2 is hydrogen, a pharmaceutically acceptable ester moiety or a conventional, readily removable protecting group or salt cation.
- R 2 ' is as defined but preferably is an ester moiety defined under R 2 '.
- R 1 ' is hydrogen or a readily removable protecting group such as a triorganosilyl group.
- antibiotics which are useful in animal and human therapy and in inanimate systems. These antibiotics are.active against a broad range of pathogens which representatively include both gram positive bacteria such as S. aureus, Strep. pyogenes, and B. subtilis, and gram negative bacteria such as E. coli, Pseudomonas, Proteus morganii, Serratia, and Klebsiella. Further objects of this invention are to provide chemical processes for the preparation of such antibiotics and their non-toxic pharmaceutically acceptable salts; pharmaceutical compositions comprising such antibiotics; and to provide methods of treatment comprising administering such antibiotics and compositions when an antibiotic effect is indicated.
- oxidation of starting material 1 is accomplished by treating 1 in a solvent such as methylene chloride, methanol, chloroform, dichloroethane, or the like, with an oxidizing agent such as ozone, or the like at a temperature of from -100° to 0°C for from 0.1 to 4 hours, followed by treating the crude product with an oxidizing agent such as m-chloroperbenzoic acid, hydrogE peroxide, peracetic acid, or the like at a temperature of from 0°C to 100°C for from 1 to 100 hours to form 2. Chirality is conveniently introduced at this stage of the synthesis.
- a solvent such as methylene chloride, methanol, chloroform, dichloroethane, or the like
- Racemic 2 can be accomplished, for example, by fractional crystallization of the carboxylate salt formed with an optically active base such as brucine, N-methylphenethylamine, N,N-dimethylphenethylamine or the like.
- an optically active base such as brucine, N-methylphenethylamine, N,N-dimethylphenethylamine or the like.
- the addition 2 ⁇ 3 is accomplished by treating 2 with 1,1'-carbonyidimidazole, or the like, in a solvent such as tetrahydrofuran, dimethoxyethane, DML, or the like, at a temperature of from 0 to 50°C, followed by the addition of 0.5 to 3.0 equivalents of (R2'O 2 CCH 2 CO 2 ) 2 Mg, at a temperature of from 0 to 50°C for from 1 to 48 hours.
- R is a readily removable carboxyl protecting group such as p-nitrobenzyl, benzyl, or the like.
- R 2 ' may be a pharmaceutically acceptable ester moiety; such ester groups are representatively mentioned below. (DMF is dimethylformamide.)
- Removal of protecting group R 1 ' (3 ⁇ 4) may be accomplished by a variety of known procedures such as hydrolysis or hydrogenation.
- R2 is a triorganosilyl group (for example, [(CH 3 ) 3 C](CH 3 ) 2 Si-) removal is typically accomplished by acidic aqueous hydrolysis of 3 in a solvent such as methanol, ethanol, tetrahydrofuran, dioxane, DMF, or the like in the presence of an acid such as hydrochloric, sulfuric, acetic or the like at a temperature of from 0 to 100°C for from 2 to 18 hours.
- a solvent such as methanol, ethanol, tetrahydrofuran, dioxane, DMF, or the like
- an acid such as hydrochloric, sulfuric, acetic or the like at a temperature of from 0 to 100°C for from 2 to 18 hours.
- the diazo species 5 is prepared from 4 by treating 4 in a solvent such as CH 3 CN, CH 2 Cl 2 , THF, or the like, with an azide such as p-carboxybenzene- sulfonylazide, toluenesulfonylazide, methanesulfonyl- azide, or the like, in the presence of a base such as triethylamine, pyridine, (C 2 H 5 ) 2 NH, or the like, for from 1 to 50 hours at 0-25°C.(THF is tetrahydrofuran.)
- a solvent such as CH 3 CN, CH 2 Cl 2 , THF, or the like
- an azide such as p-carboxybenzene- sulfonylazide, toluenesulfonylazide, methanesulfonyl- azide, or the like
- a base such as triethylamine, pyridine,
- Cyclization (5 ⁇ 6) is accomplished by treating 5 in a solvent such as benzene, toluene, THF, or the like, at a temperature of from 50-110°C for from 1-5 hours in the presence of a catalyst such as bis (acetylacetonato)Cu(II) [Cu(acac) 2 ], CuSO 4 , Cu powder, Rh(OAc) 2 , or Pd(OAC) 2 .
- a solvent such as benzene, toluene, THF, or the like
- the cyclization may be accomplished by irradiating 6 througn a pyrex filter (a wave length greater than 300nm) in a solvent such as benzene, CCl 4 , diethylether, or the like, at a temperature of from 0-25°C for from 0.5 to 2 hours.
- a solvent such as benzene, CCl 4 , diethylether, or the like
- Establishment of leaving group X (6 ⁇ 7) is accomplished by acylating the keto ester 6 with an acylating agent R°X such as p-toluenesulfonic acid anhydride, p-nitrophenylsulfonic acid anhydride, 2,4,6-triisopropylphenylsulfonic acid anhydride, methanesulfonic acid anhydride, trifluoromethane sulfonic acid anhydride, diphenyl chlorophosphate,toluenesulfonyl chloride, p-bromophenylsulfonyl chloride, or the like ; wherein X is the corresponding leaving group such as toluene sulfonyloxy, p-nitrophenylsulfonyloxy, diphenylphosphoryl, and other leaving groups which are established by conventional procedures and are well known in the art.
- R°X such as p-toluenesulfonic acid anhydride
- the above acylation to establish leaving groups X is conducted in a solvent such as methylene chloride, acetonitrile or dimethylformamide, in the presence of a base such as diisopropylethylamine, triethylamine, 4-dimethylamino-pyridine or the like at a temperature of from -20 to 40°C for from 0.1 to 5 hours.
- a solvent such as methylene chloride, acetonitrile or dimethylformamide
- the leaving group X of intermediate 7 can also be halogen.
- the halogen leaving group is established by treating 7 with a halogenating agent such as ⁇ 3 PCl 2 , ⁇ 3 PBr 2 , ( ⁇ ) 3 PBr 2 , oxalyl chloride or the like in a solvent such as CH 2 Cl 2 , CH 3 CN, THF, or the like in the presence of a base such as diisopropylethylamine, triethylamine, or 4-dimethylaminopyridine or the like.
- a halogenating agent such as ⁇ 3 PCl 2 , ⁇ 3 PBr 2 , ( ⁇ ) 3 PBr 2 , oxalyl chloride or the like
- a solvent such as CH 2 Cl 2 , CH 3 CN, THF, or the like
- a base such as diisopropylethylamine, triethylamine, or 4-dimethylaminopyridine or the like.
- the reaction 7 ⁇ 8 is accomplished by treating 7 in a solvent such as dioxane, dimethylformamide, dimethylsulfoxide, acetonitrile, hexamethylphosphoramide, or the like in the presence of an approximately equivalent to excess of the mercaptan reagent H SR $ ,wherein R 8 is as defined above, in the presence of a base such as sodium hydrogen carbonate, potassium carbonate, triethylamine, diisopropylethylamine, or the like at a temperature of from -40 to 25°C for from 1 to 72 hours.
- a solvent such as dioxane, dimethylformamide, dimethylsulfoxide, acetonitrile, hexamethylphosphoramide, or the like
- a base such as sodium hydrogen carbonate, potassium carbonate, triethylamine, diisopropylethylamine, or the like at a temperature of from -40 to 25°C for from 1 to 72 hours.
- the mercaptan reagent may be represented as HSCH 2 CH 2 NHR°, for example; wherein R° is a readily removable N-protecting group such as p-nitrobenzyloxycarbonyl, (-C0 2 PNB), o-nitrobenzyloxycarbonyl, or the like.
- the specifically illustrated mercaptan reagent, HSCH 2 CH 2 NHR° is typically prepared by treating aminoethylmercaptan in the presence of the desired acid chloride in the presence of a base such as sodium bicarbonate, sodium hydroxide, or the like in a solvent such as aqueous diethylether, aqueous dioxane, aqueous acetone, or the like at a temperature of from 0 to 25°C for from 0.5 to 4 hours.
- a base such as sodium bicarbonate, sodium hydroxide, or the like
- a solvent such as aqueous diethylether, aqueous dioxane, aqueous acetone, or the like at a temperature of from 0 to 25°C for from 0.5 to 4 hours.
- HSR 8 and means for its protection, is simply illustrative.
- the class of suitable HSR S reagents is representatively described below and in the Examples.
- the final deblocking step 8 ⁇ I is accomplished by conventional procedures such as solvolysis or hydrogenation.
- a solvent such as dioxane-water-ethanol, tetrahydrofuran-aqueous dipotassium hydrogen phosphate-isopropanol or the like is treated under a hydrogen pressure of from 1 to 4 atmospheres in the presence of a hydrogenation catalyst such as palladium on charcoal, palladium hydroxide, platinum oxide, or the like at a temperature of from 0 to 50°C for from 0.25 to 4 hours to provide I.
- a hydrogenation catalyst such as palladium on charcoal, palladium hydroxide, platinum oxide, or the like at a temperature of from 0 to 50°C for from 0.25 to 4 hours.
- Photolysis when R 2 is a group such as o-nitrobenzyl, for example, may also be used for deblocking.
- suitable reagents HSR 8 utilized in the transformation 7 ⁇ 8 are listed below. The list is arranged according to structural and functional characteristics of the thia side chain -SR 8 ; annotation is provided where necessary.
- the thia side chain of choice is derived from the corresponding mercaptan reagent HSR 8 . When the mercaptan contains a functional group which might interfere with the intended course of reaction, the offending group is covered.
- acylation e.g., -C0 2 PNB
- carboxyl group e.g., PNB ester
- PNB p-nitrobenzyl
- Aliphatic (including carbocyclic) Mercaptans HSR wherein R 8 is 1-10 carbon alkyl, cycloalkyl, alkenyl, cycloalkenyl, or alkynyl; R 8 may be branched or unbranched, Examples
- Substituted Aliphatic Mercaptans HSR 8 wherein R 8 is a 1-10 carbon branched or unbranched alkyl, cycloalkyl, alkenyl, cycloalkenyl or alkynyl group substituted by one or more halo, OH, OR 1 , NH 2 , NHR 1 , NR 1 R 2 , CO 2 H, CO 2 R 1 , CONH 2 , CONHR 1 , CONR 1 R 2 , CN, ⁇ R 1 , SO 2 R 1 , SO 2 NH 2 , SO 2 NHR 1 , SO 2 NR 1 R 2 , wherein R 1 and R 2 are as previously defined relative to substituents on R8.
- Preferred substituents are basic nitrogen containing groups.
- Aryl Mercaptans HSR 8 wherein R 8 is phenyl or substituted phenyl.
- the substituents are independently selected from those previously defined for R 8 .
- Especially preferred substituents include alkyl, halo, hydroxy, alkoxy, acyloxy, acyl, carboxy, mercapto, sulfinyl, sulfonyl, amino, substituted amino, aminoalkyl, substituted aminoalkyl, amido, and ureido.
- X F, Cl, Br, OH, OR, OCR 1 , NH 2 , NHR 1 , NR 1 R 2 , CH 2 NH 2 , CH 2 NR 1 R 2 , CO 2 H, CO 2 R 1 COR 1 , CONH 2 , CONR 1 R 2 , R 1 CONH, CO 2 R 1 , COR 1 , CONH 2 , CONR 1 R 2 , R 1 CONH, R 1 NHCONH, SR 1 , SR 1 , SO 2 R 1 , CH 3 , CF 3 ; R 1 and R 2 are as previously defined under R 8 .
- Heteroaryl Mercaptans HSR 8 wherein R 8 is a substitu unsubstituted heteroaryl group containing 1-4 O, N or S atoms. Typical substituents include those mentioned above under "Aryl Mercaptans”.
- Arylaliphatic Mercaptans HSR8 where R 8 is a 1-6 carbon branched or unbranched alkyl, cycloalkyl, alkenyl, or alkynyl group substituted by a phenyl or substituted phenyl group.
- Typical phenyl substituents include those mentioned under "Aryl Mercaptans”.
- R 8 is a 1-6 carbon branched or unbranched alkyl, cycloalkyl, alkenyl, or alkynyl group substituted by a heteroaryl or heterocyclic group containing 1-4, O, N , or S atoms.
- the heteroaryl or heterocyclic group is unsubstituted or substituted by those substituents mentioned under "Aryl Mercaptans", (No.3, above).
- the methylene carbons may be branched; for example: and the like.
- HSR 8 are representative of this class:
- Starting material 1 is conveniently prepared from 4-allylazetidinone according to the following scheme:
- R is a removable blocking group such as triorganosilyl, for example, trimethylsilyl, t-butyldimethylsilyl, triphenylsilyl, and the like.
- starting material la can be mono-, or dialkylated at ring position 3.
- Alkylation of la provides b.
- la is treated with a strong base such as lithium diisopropylamide, lithium 2,2,6,6-tetramethylpiperidide, potassium hydride, lithium hexamethyldisilazane, phenyllithium or the like in a solvent such as tetrahydrofuran (THF), hexamethylphosphoramide, ether, dimethoxyethane, and the like at a temperature of from -80°C to 0°C whereupon the alkylating agent of choice, R 6 X° is added (X° is chloro, iodo or bromo); alternatively the alkylating agent may be R 6- tosylate, R 6- mesylate or an aldehyde or ketone such as acetaldehyde to provide monoalkylated species lb.
- a strong base such as lithium diisopropyl
- dialkylated species 1 may be obtained from 1b by repeating the alkylating procedures 1a ⁇ 1b.
- the 6-substituents can also be established by direct acylation using an acylating agent such as N-acyl imidazole or the like.
- acylating agent such as N-acyl imidazole or the like.
- N-acyl imidazole acylating reagents are listed below. Also given below is a detailed description of this second approach for establishing, R 6 and R 7 .
- the 6-substituents may also be established by acylation.
- acylating agents may be demonstrated in the following manner with regard to a preferred starting material 1: wherein R 7 and R 1' are as defined above.
- R 6' is defined relative to the definition of R 6 and in that sense is the balance of the previously identified group R6.
- R6'CH(OH)- R 6 .
- An especially preferred material 1 is when R 7 is hydrogen and R 6 ' is methyl.
- Such preferred starting materials are described in the following co-pending, commonly assigned U.S. Patent Application Serial Number 59,842 filed July 23, 1979 which is incorporated herein by reference. Basically, such I'-hydroxy R 6 ' species 1 are prepared according to the following scheme: SCHEME II
- the alkylation 1a ⁇ 1, Scheme II, is accomplished as previously described, by treating 1a in a solvent such as tetrahydrofuran, dimethoxyethane, diethylether, hexamethylphosphoramide, at a temperature of from -100° to -20°C with a strong base such as lithium diisopropylamide, lithium hexamethyldisilazide, lithium 2,2,6,6-tetramethylpiperidide, potassium hydride or the like followed by the addition of an equivalent to 10 fold excess of an aldehyde.
- This reaction gives a mixture of isomers from which the desired trans-R form 1 can be conveniently separated by chromatography or crystallization.
- Intermediate la may proceed directly to 1 as indicated above, or it may take the circuitous path via 1'.
- the direct acylation, to 1' is accomplished by treating 1a with two or more equivalents of a base such as lithium diisopropylamide, lithium hexamethyldisilazide, lithium 2,2,6,6-tetramethylpiperidide, in a solvent such as tetrahydrofuran, diethylether, or dimethoxyethane, for example, at a temperature of from -100 to -20°C with an acylating agent such as N-acyl imidazole or the like. Addition of the-la plus base mixture to the acylating agent is preferred.
- the reduction, 1' ⁇ 1 is accomplished by contacting the ketone with a reducing agent such as potassium tri(sec-butyl)borohydride, lithium tri(sec-butyl)borohydride, sodium bprohydride, sodium tris(methoxyethoxy)aluminum hydride, lithium aluminum hydride or the like in a solvent such as diethylether, tetrahydrofuran, toluene or the like at a temperature of from -78° to 25° C .
- a reducing agent such as potassium tri(sec-butyl)borohydride, lithium tri(sec-butyl)borohydride, sodium bprohydride, sodium tris(methoxyethoxy)aluminum hydride, lithium aluminum hydride or the like in a solvent such as diethylether, tetrahydrofuran, toluene or the like at a temperature of from -78° to 25° C .
- the reaction can conveniently be conducted in the presence
- unresolved 1 (cis and trans) may be oxidized to 1' for reduction to 1 as indicated above:
- the oxidation is accomplished with an oxidizing agent such as dipyridine chromium (VI) oxide, trifluoroacetic anhydride-dimethylsulfoxide-triethylamine, pyridinium dichromate, acetic anhydride-dimethylsulfoxide in a solvent such as methylene chloride, acetonitrile, or the like at a temperature of from -78 to 25°C for from 5 minutes to 5 hours.
- an oxidizing agent such as dipyridine chromium (VI) oxide, trifluoroacetic anhydride-dimethylsulfoxide-triethylamine, pyridinium dichromate, acetic anhydride-dimethylsulfoxide in a solvent such as methylene chloride, acetonitrile, or the like at a temperature of from -78 to 25°C for from 5 minutes to 5 hours.
- the compounds of the present invention may also generally be represented by the following structural formula: wherein X 1 is oxygen, sulfur or NR' (R'is hydrogen or loweralkyl having from 1 to 6 carbon atoms); and R 31 is hydrogen, or, inter alia, is representatively selected to provide the pharmaceutically acceptable salt, ester anhydride (R 3' is acyl) and amide moieties known in the bicyclic ⁇ -lactam antibiotic art; R 3' may also be a readily removable blocking group. Identification of the Radical -COX'R 3'
- the radical represented by -COX'R 3' is, inter alia, -COOH (X' is oxygen and R 3' is hydrogen) and all radicals known to be effective as pharmaceutically acceptable ester, anhydride (R 3' is acyl) and amide radicals in the bicyclic ⁇ -lactam antibiotic art, such as the cephalosporins and penicillins and nuclear analogues thereof.
- Silyl esters under this category of blocking groups, may conveniently be prepared from a halosilane of the formula: R 4 3 SiX' wherein X' is a halogen such as chloro or bromo and R is alkyl, e.g., methyl,-ethyl, t-butyl.
- esters and amides of interest are the above-listed starting materials and final products having the -COX'R 3' group at the 3-position; wherein X' is oxygen, sulfur or NR' (R' is H or R 3' ), and R 31 is alkyl having 1-6 carbon atoms, straight or branched, such as methyl, ethyl, t-butyl, and the like; carbonylmethyl, including phenacyl; aminoalkyl including 2-methylaminoethyl, 2-diethylaminoethyl; alkanoyloxyalkyl wherein the alkanoyloxy portion is straight or branched and has 1-6 carbon atoms and the alkylportion has 1-6 carbon atoms, such as pivaloyloxymethyl; haloalkyl wherein halo is chloro, and the alkyl
- amides are also embraced by the present invention, i.e., wherein X' is the -N- group.
- Representative of such amides are those wherein R' is selected from the group consisting of hydrogen and lower alkyl such as methyl and ethyl.
- the most preferred -COX' R 3' radicals of the present invention are those wherein (relative to Structure I above), X' is oxygen and R 3' is hydrogen; loweralkyl having 1-4 carbon atoms; lower alkenyl such as 3-methylbutenyl, 4-butenyl and the like; benzyl and substituted benzyl such as p-nitrobenzyl; pivaloyloxymethyl, 3-phthalidyl; and phenacyl.
- the compounds of the present invention are valuable antibiotics active against various gram-positive and gram-negative bacteria and accordingly.find utility in human and veterinary medicine.
- Representative pathogens which are sensitive to antibiotics I include: S taphyloccus aureus, Escherichia coli, Klebsiella pneumoniae, Bacillus subtilis, Salmonella typhosa, p suedomonas and Bacterium proteus.
- the antibacterials of the invention are not limited to utility as medicaments; they may be used in all manner of industry, for example: additives to animal feed, preservation of food, disinfectants, and in other industrial systems where control of bacterial growth is desired.
- compositions may be employed in aqueous compositions in concentrations ranging from 0.1 to 100 parts of antibiotic per million parts of solution in order to destroy and inhibit the growth of harmful bacteria on medical and dental equipment and as bactericides in industrial applications, for example in waterbased paints and in the white water of paper mills to inhibit the growth of harmful bacteria.
- the products of this invention may be used in any of a variety of pharmaceutical preparations. They may be employed in capsule, powder form, in liquid solution, or in suspension. They may be administered by a variety of means; those of principal interest include: orally, topically or parenterally by injection (intravenously or intramuscularly).
- Such tablets and capsules designed for oral administration, may be in unit dosage form, and.may contain conventional excipients, such as binding agents, for example, syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example, lactose, sugar, cornstarch, calcium phosphate, sorbitol, or glycerine; lubricants, for example, magnesium stearate, talc, polyethylene glycol, silica; disintegrants, for example, potato starch; or acceptable wetting agents such as sodium lauryl sulphate.
- the tablets may be coated according to methods well known in the art.
- Oral liquid preparations may be in the form of aqueous or oily suspensions, or solutions, or they may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
- Such liquid preparations may contain conventional additives such as suspending agents, for example, sorbitol, methyl cellulose, glucose/sugar syrup, gelatin,- hydroxyethylcellulose, or carboxymethyl cellulose.
- Suppositories will contain conventional suppository bases, such as cocoa butter or other glycerides.
- compositions for injection may be prepared in unit dosage form in ampules, cr in multidose containers.
- the compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous-vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- the active ingredient may be in powder form for reconstitution, at the time of delivery, with a suitable vehicle, such as sterile water.
- compositions may also be prepared in suitable forms for absorption through the mucous membranes of the nose and throat or bronchial tissues and may conveniently take the form of liquid sprays or inhalants, lozenges, or throat paints. For medication of the eyes or ears, the preparation may be presented in liquid or semi-solid form.
- Topical applications may be formulated in hydrophobic or hydrophilic bases as ointments, creams, lotions, paints, or powders.
- a daily dosage consists of from about 5 to about 600 mg of active ingredient per kg. of body weight of the subject in one or more treatments per day.
- a preferred daily dosage for adult humans lies in the range of from about 10 to 240 mg. of active ingredient per kg. of body weight.
- Another factor influencing the precise dosage regimen, apart from the nature-of the infection and peculiar identity of the individual being treated, is the molecular weight of the chosen species of this invention (I).
- compositions for human delivery per unit dosage may contain from 0.1 % to 99% of active material, the preferred range being from about 10-60%.
- the composition will generally contain from about 15 mg. to about 1500 mg. of the active ingredient; however, in general, it is preferable to employ a dosage amount in the range of from about 250 mg to 1000 mg.
- the unit dosage is usually the pure compound I in sterile water solution or in the form of a soluble powder intended for solution.
- the pH of such solutions typically will correspond to the zwitterionic point; however, consideration of individual properties of solubility and stability may require such aqueous solutions to have a pH other than that of the zwitterionic point, for example in the range of 5.5 to 8.2.
- t-Butyldimethylchlorosilane (7.51 g, .49.8 mmol) is added in one portion to an ice-cold, stirring solution of 4-(prop-2-ene)-azetidin-2-one (5.26 g, 47.4 mmol) and triethylamine (5.04 g 49.8 mmol) in anhydrous dimethylformamide (100 ml).
- a voluminous white precipitate forms almost immediately.
- the reaction mixture is stirred at 0-5° for 1 hour and then allowed to warm to room temperature. Most of the solvent is removed under vacuum to give a residue which is partitioned between diethyl ether (250 ml) and water.
- n-Butyllithium in hexane (26.25 mmol) is added slowly by syringe to a solution of diisopropylamine (26.25 mmol) in anhydrous tetrahydrofuran (100 ml) at -78°C.
- the resulting solution is stirred for 15 min prior to the addition of a solution of l-(t-butyldimethylsilyl)-4-(prop-2-ene)-azetidin-2- one (25.0 mmol) in anhydrous tetrahydrofuran (25 ml).
- the second fraction is a mixture of the trans R * and S * products (5.56 g). Crystallization of this material from petroleum ether gives the pure trans R * material, m.p. 81-82°C.
- Trifluoroacetic anhydride (7.5 mmol) is added dropwise by syringe to a solution of dimethylsulfoxide (10 mmol) in anhydrous methylene chloride (15 ml) at -78°C. The resulting mixture is stirred at -78°C for 20 min. during which time a white precipitate forms.
- a solution of 1-(t-butyldimethylsilyl)-3-(1-hydroxyethyl)-4-(prop-2-ene)-azetidin-2-one (5.0 mmol) in methylene chloride (15 ml) is added by syringe and the resulting solution is stirred at -78°C for 30 min.
- Triethylamine 14 mmol is added by syringe and the cooling bath is removed. After an additional 1 hr., the reaction mixture is diluted with methylene chloride (100 ml), washed with water (50 ml) and brine and dried over magnesium sulfate. Removal of solvents in vacuo yields an oil which is chromatographed on silica gel (2:1, petroleum ehter:ether) to yield (3S*,4R*)-1-(t-butyldimethylsilyl-3-(1--oxoethyl)-4-(prop-2-ene)-azetidin-2-one. I.R.
- reaction mixture is added via a Teflon tube to a mixture of N-acetylimidazole (4.1 mmol) in anhydrous tetrahydrofuran (16 ml) at -78°C.
- the resulting yellow reaction mixture is stirred at -78°C for 15 min, then quenched by addition of saturated aqueous ammonium chloride solution (10 ml).
- the reaction mixture is diluted with ether (100 ml) and washed with 2.5N hydrochloric acid solution (25 ml) water (25 ml) and brine.
- the organic phase is dried over magnesium sulfate and concentrated in vacuo to yield an oil.
- K-Selectride (potassium tri-(sec)-butylborohydride) in tetrahydrofuran (4.8 mmol) is added by syringe to a mixture of potassium iodide (2.0 mmol) and (3S * , 4R*)-1-(t-butyldimethylsilyl)-3-(1-oxoethyl)-4-(prop-2-ene)-azetidin-2-one (2.0 mmol) in anhydrous ether (20 ml) at room temperature. The resulting mixture is stirred at room temperature for 2.5 hours, then quenched by addition of glacial acetic acid (9.6 mmol).
- the resulting mixture is stirred at room temperature for 1 hr, then the tetrahydrofuran is removed at the pump and the gummy residue is triturated with ether to yield the magnesium salt as an off-white solid.(1.1 mmol) of this magnesium salt is then added to the first reaction flask and the resulting mixture is stirred at room temperature for 18 hrs. The reaction mixture is then poured into 50 ml of ether, washed with 0.5N hydrochloric acid solution (20 ml), water (20 ml), saturated aqueous sodium bicarbonate solution (20 ml), brine and dried over magnesium sulfate.
- Triethylamine (263 mg, 2.6 mmol) is added by syringe to a mixture 'of (3S*, 4R*)-3- [(R*)-1-hydroxyethyl] -4- [3- (4-nitrobenzyl)oxycarbonyl-2-oxopropyl]azetidin-2-one (253 mg, 0.72 mmol) and p-carboxybenzene sulfonylazide (196 mg, 0.84 mmoll in dry acetonitrile (6 ml) at 0°C. When addition is complete the cooling bath is removed and the reaction mixture is stirred at room temperature for 1 hour.
- the ether layer is extracted with 150 ml 0.25 N HCl, and then with 200 ml brine. Each aqueous layer is then backwashed successively with 100 ml Et 2 O. The combined Et 2 0 layers are dried over anhydrous MgS0 4 , filtered, and concentrated under a N 2 stream. The crystalline residue is slurried in a small amount of ether, filtered, and the pale yellow crystals are dried under high vacuum to give 4.7 g. p-nitrobenzyloxycarbonylaminoethanethiol (65% yield). NMR (CDCl 3 ).
- Diisopropylethylamine (22 mg, 0.17 mmol) is added by syringe and the resulting solution is stirred at 0°C for 1 minute prior to the addition of a solution of freshly recrystallized p-toluene sulfonic anhydride (51 mg, 0.156 mmol) in dry acetonitrile (1 ml).
- Trifluoroacetic anhydride (180 ⁇ l, 1.28 mmol) is added dropwise by syringe to a solution of dimethylsulfoxide (120 ⁇ l, 1.69 mmol) in anhydrous methylene chloride (2.5 ml) at -78°C under N 2 . The resulting mixture is stirred at -78°C for 15 min.
- a solution of 1-(t-butyldimethylsilyl)-3-(1-hydroxyethyl)-3 ⁇ -methyl 4-(prop-2-en)-azetidin-2-one (234 mg, 0.83 mmol) in methylene chloride (2 ml) is added, and the resulting solution is stirred at -78°C for 1 hr.
- Triethylamine (382 ⁇ l, 2.76 mmol) is added by syringe, and the cooling bath is removed. After an additional 1 hr, the reaction mixture is diluted with methylene chloride, washed with water and brine, dried over magnesium sulfate, filtered. Removal of solvents in vacuo yields partially crystalline oil. Chromatography on silica gel (0-10% ether:petroleum ether) provides 191 mg of the title compound.
- 1,1'-Carbonyldiimidazole (1.09mg, 0.67mmol) is added in one portion to a solution of 251 mg l-(t-butyldimethylsilyl)-3-(l-t-butyldimethylsilyloxyethyl)-3S-methyl-4-(carboxymethyl)-azetidin-2-one (0.60 mmol) in anhydrous tetrahydrofuran (3 ml) at room temperature under N 2 . The resulting solution is stirred at room temperature for 3.5 hours.
- magnesium ethoxide (5 mmol) is added in one portion to a solution of the mono-p-nitrobenzyl ester of malonic acid (10 mmol) in anhydrous tetrahydrofuran (25 ml).
- the resulting mixture is stirred at room temperature for 1 hr, then the tetrahydrofuran is removed at the pump, and the gummy residue is triturated with ether to yield the magnesium salt as an off-white solid.
- the magnesium salt (339 mg, 0.678 mmol) is then added to the first reaction flask and the resulting mixture is stirred at room temperature overnight.
- Triethylamine (55 ⁇ l, 0.397 mmol) is added by syringe to a mixture of 3-(1-hydroxyethyl)-3 ⁇ -methyl-4-[3-(p-nitrobenzyl)oxycarbonyl-2-oxopropyl]-azetidin-2-one (40 mg, 0.11 mmol) and p-carboxybenzene sulfonylazide (30 mg, 0.13 mmol) in dry acetonitrile (1 ml) at 0°C.
- the cooling bath is removed, and the reaction mixture is stirred at room temperature for 1.5 hour. The mixture is then diluted with ethyl acetate (10 ml) and filtered.
- the crude bicycloketone (32.5 mg, 0.09 mmol) is dissolved in anhydrous acetonitrile (1.8 ml), and the resulting solution is cooled to 0°C under N 2 .
- Diisopropylethylamine (18.9 ⁇ l, 0.11 mmol) is added followed by diphenylchlorophosphate (19.9 ⁇ l, 0.10 mmol), and the resulting solution is stirred at 0°C for 55 min.
- Diisopropylethylamine (17.7 ⁇ l, 0.10 mmol) is added by syringe followed by p-nitrobenzyloxycarbonylaminoethanethiol (26.6 mg, 0.104 mmol), and the reaction is stirred for 2.5 hr.
- the reaction mixture is centrifuged, and the supernatant is filtered through a small plug of cotton into a cold centrifuge tube.
- the residual catalyst is washed (3X) with 15 drops DI-H 2 0 and centrifuged; the supernatants are added to the original filtrate which is finally extracted with ethylacetate (3 x 1 ml).
- the aqueous layer is briefly placed on an aspirator to remove residual organic solvents and then applied to a small column of XAD-2 resin ( ⁇ 7ml vol) packed and eluted with DI-H 2 0. After the first 2.5 ml, the next 30 ml eluant contains the product.
- the above sequence is repeated on 5.4mg and 5.0 mg additional starting material.
- the combined aqueous solutions are concentrated in vacuo without heat to 3 ml volume.
- the solution is passed portionwise through a semi-prep (9.5ml void volume) ⁇ -Bondapak-C 18 HPLC column (3% THF/DI-H 2 0, flow rate-2 ml/min, 254m ⁇ filter), and the major peak is collected.
- Example 2 Following the procedure of Example 2, the azetidinones of Table I are obtained when the basic procedure of Example 2 is modified according to the remarks entered in Table I.
- Example 9 the representative intermediates of the present invention are obtained when the indicated substitution from Example 14 is made into the scheme of Example 9.
- the compounds of the present invention may also be prepared by the processes disclosed and claimed in the three (3) following, co-pending, commonly assigned U.S. Patent Applications of Christensen, Ratcliffe and Salzmann. To the extent that these applications define R 6 , R 7 , and R 8 of Structure I and to the extent that they describe processes for the synthesis of intermediates III and IV (defined above) they are hereby incorporated by reference. wherein R 6 , R 7 and X are defined above.
Abstract
Processes and intermediates for the total synthesis of 1-carbapenem antibiotics (I) via intermediates (III) and (IV):
wherein R is hydrogen, a pharmaceutically acceptable ester moiety or salt cation, or a readily removable blocking group; R6, R7 and R8 are, inter alia, independently selected from the group consisting of hydrogen, alkyl, alkenyl, aryl and aralkyl, and X is a conventional leaving group.
Description
- This invention relates to the total synthesis of certain 1-carbapenems and their pharmaceutically acceptable salt, ester and amide derivatives which are useful as antibiotics. Such compounds may generically be represented by the following structural formula:
- This invention also relates to the carboxyl derivatives of I which are antibiotics and which may be represented by the following generic structure (I) :
- Starting from an appropriately substituted 4-allylazetidinone (II), the synthesis proceeds via intermediates III and IV:
- The details of the total synthesis are given below.
- The final compounds prepared by the process of this invention are disclosed and claimed in the following co-pending European Patent Application Serial Number 78 101 156 filed October 16, 1978; European Patent Application Serial Number 80 102 076 filed April 18, 1980 and European Patent Application Serial Number 78 101 157 filed October 16, 1978. To the extent that the foregoing Patent Applications' describe the antibiotic utility of final compound I and to the extent that they define substituents R 6, R7, R 8, R', X' and R3Ithey are hereby incorporated by reference.
- Thus, it is an object of the present invention to provide a novel class of antibiotics which are useful in animal and human therapy and in inanimate systems. These antibiotics are.active against a broad range of pathogens which representatively include both gram positive bacteria such as S. aureus, Strep. pyogenes, and B. subtilis, and gram negative bacteria such as E. coli, Pseudomonas, Proteus morganii, Serratia, and Klebsiella. Further objects of this invention are to provide chemical processes for the preparation of such antibiotics and their non-toxic pharmaceutically acceptable salts; pharmaceutical compositions comprising such antibiotics; and to provide methods of treatment comprising administering such antibiotics and compositions when an antibiotic effect is indicated.
- The process of the present invention may conveniently be summarized by the following reaction diagram:
-
- In words relative to Diagram I, oxidation of starting material 1 (described below) is accomplished by treating 1 in a solvent such as methylene chloride, methanol, chloroform, dichloroethane, or the like, with an oxidizing agent such as ozone, or the like at a temperature of from -100° to 0°C for from 0.1 to 4 hours, followed by treating the crude product with an oxidizing agent such as m-chloroperbenzoic acid, hydrogE peroxide, peracetic acid, or the like at a temperature of from 0°C to 100°C for from 1 to 100 hours to form 2. Chirality is conveniently introduced at this stage of the synthesis. Resolution of racemic 2 can be accomplished, for example, by fractional crystallization of the carboxylate salt formed with an optically active base such as brucine, N-methylphenethylamine, N,N-dimethylphenethylamine or the like.
- The addition 2 → 3 is accomplished by treating 2 with 1,1'-carbonyidimidazole, or the like, in a solvent such as tetrahydrofuran, dimethoxyethane, DML, or the like, at a temperature of from 0 to 50°C, followed by the addition of 0.5 to 3.0 equivalents of (R2'O2CCH2CO2)2Mg, at a temperature of from 0 to 50°C for from 1 to 48 hours. R is a readily removable carboxyl protecting group such as p-nitrobenzyl, benzyl, or the like. It should also be noted that R2' may be a pharmaceutically acceptable ester moiety; such ester groups are representatively mentioned below. (DMF is dimethylformamide.)
- Removal of protecting group R1' (3 →4) may be accomplished by a variety of known procedures such as hydrolysis or hydrogenation. When R2 is a triorganosilyl group (for example, [(CH3)3C](CH3)2Si-) removal is typically accomplished by acidic aqueous hydrolysis of 3 in a solvent such as methanol, ethanol, tetrahydrofuran, dioxane, DMF, or the like in the presence of an acid such as hydrochloric, sulfuric, acetic or the like at a temperature of from 0 to 100°C for from 2 to 18 hours.
- It should be noted that an otherwise identical deblocking can occur on 1 or 2. Thus, when R1'=H, the chain elongation can proceed directly from 2 to 4.
- The diazo species 5 is prepared from 4 by treating 4 in a solvent such as CH3CN, CH2Cl2, THF, or the like, with an azide such as p-carboxybenzene- sulfonylazide, toluenesulfonylazide, methanesulfonyl- azide, or the like, in the presence of a base such as triethylamine, pyridine, (C2H5)2NH, or the like, for from 1 to 50 hours at 0-25°C.(THF is tetrahydrofuran.)
- Cyclization (5→6) is accomplished by treating 5 in a solvent such as benzene, toluene, THF, or the like, at a temperature of from 50-110°C for from 1-5 hours in the presence of a catalyst such as bis (acetylacetonato)Cu(II) [Cu(acac)2], CuSO4, Cu powder, Rh(OAc)2, or Pd(OAC)2. Alternatively, the cyclization may be accomplished by irradiating 6 througn a pyrex filter (a wave length greater than 300nm) in a solvent such as benzene, CCl4, diethylether, or the like, at a temperature of from 0-25°C for from 0.5 to 2 hours. ["OAc" = acetate.]
- Establishment of leaving group X (6 → 7) is accomplished by acylating the keto ester 6 with an acylating agent R°X such as p-toluenesulfonic acid anhydride, p-nitrophenylsulfonic acid anhydride, 2,4,6-triisopropylphenylsulfonic acid anhydride, methanesulfonic acid anhydride, trifluoromethane sulfonic acid anhydride, diphenyl chlorophosphate,toluenesulfonyl chloride, p-bromophenylsulfonyl chloride, or the like;wherein X is the corresponding leaving group such as toluene sulfonyloxy, p-nitrophenylsulfonyloxy, diphenylphosphoryl, and other leaving groups which are established by conventional procedures and are well known in the art. Typically, the above acylation to establish leaving groups X is conducted in a solvent such as methylene chloride, acetonitrile or dimethylformamide, in the presence of a base such as diisopropylethylamine, triethylamine, 4-dimethylamino-pyridine or the like at a temperature of from -20 to 40°C for from 0.1 to 5 hours.
- The leaving group X of intermediate 7 can also be halogen. The halogen leaving group is established by treating 7 with a halogenating agent such as φ3PCl2, φ3PBr2, (φ)3PBr2, oxalyl chloride or the like in a solvent such as CH2Cl2, CH3CN, THF, or the like in the presence of a base such as diisopropylethylamine, triethylamine, or 4-dimethylaminopyridine or the like. [Ø = phenyl.]
- The reaction 7→ 8 is accomplished by treating 7 in a solvent such as dioxane, dimethylformamide, dimethylsulfoxide, acetonitrile, hexamethylphosphoramide, or the like in the presence of an approximately equivalent to excess of the mercaptan reagent HSR$,wherein R8 is as defined above, in the presence of a base such as sodium hydrogen carbonate, potassium carbonate, triethylamine, diisopropylethylamine, or the like at a temperature of from -40 to 25°C for from 1 to 72 hours. When R8 is substituted by a primary or secondary amino group, for example -CH2CH2NH2, the mercaptan reagent may be represented as HSCH2CH2NHR°, for example; wherein R° is a readily removable N-protecting group such as p-nitrobenzyloxycarbonyl, (-C02PNB), o-nitrobenzyloxycarbonyl, or the like. The specifically illustrated mercaptan reagent, HSCH2CH2NHR°, is typically prepared by treating aminoethylmercaptan in the presence of the desired acid chloride in the presence of a base such as sodium bicarbonate, sodium hydroxide, or the like in a solvent such as aqueous diethylether, aqueous dioxane, aqueous acetone, or the like at a temperature of from 0 to 25°C for from 0.5 to 4 hours. The foregoing mercaptan reagent, HSR8, and means for its protection, is simply illustrative. The class of suitable HSRS reagents is representatively described below and in the Examples.
- The final deblocking step 8→I is accomplished by conventional procedures such as solvolysis or hydrogenation. Typically 8 in a solvent such as dioxane-water-ethanol, tetrahydrofuran-aqueous dipotassium hydrogen phosphate-isopropanol or the like is treated under a hydrogen pressure of from 1 to 4 atmospheres in the presence of a hydrogenation catalyst such as palladium on charcoal, palladium hydroxide, platinum oxide, or the like at a temperature of from 0 to 50°C for from 0.25 to 4 hours to provide I. Photolysis, when R2 is a group such as o-nitrobenzyl, for example, may also be used for deblocking.
-
-
- 2.) Substituted Aliphatic Mercaptans: HSR8 wherein R 8 is a 1-10 carbon branched or unbranched alkyl, cycloalkyl, alkenyl, cycloalkenyl or alkynyl group substituted by one or more halo, OH, OR1,
-
- 3.) Aryl Mercaptans: HSR8 wherein R8 is phenyl or substituted phenyl. The substituents are independently selected from those previously defined for R8. Especially preferred substituents include alkyl, halo, hydroxy, alkoxy, acyloxy, acyl, carboxy, mercapto, sulfinyl, sulfonyl, amino, substituted amino, aminoalkyl, substituted aminoalkyl, amido, and ureido.
-
- 4.) Heteroaryl Mercaptans: HSR8 wherein R8 is a substitu unsubstituted heteroaryl group containing 1-4 O, N or S atoms. Typical substituents include those mentioned above under "Aryl Mercaptans".
-
- 5.) Arylaliphatic Mercaptans: HSR8 where R8 is a 1-6 carbon branched or unbranched alkyl, cycloalkyl, alkenyl, or alkynyl group substituted by a phenyl or substituted phenyl group. Typical phenyl substituents include those mentioned under "Aryl Mercaptans".
-
- HSR8 wherein R8 is a 1-6 carbon branched or unbranched alkyl, cycloalkyl, alkenyl, or alkynyl group substituted by a heteroaryl or heterocyclic group containing 1-4, O, N, or S atoms. The heteroaryl or heterocyclic group is unsubstituted or substituted by those substituents mentioned under "Aryl Mercaptans", (No.3, above).
-
- 7.) Alkyl-Heteroatom-Alkyl Mercaptans, HSR8 Wherein R8 is -(CH2)nX(CH2)mR9 wherein n = 2 to 4, m = 2 to 4; X is NR°, 0 or S; and wherein R° is H, CH3, CH2CH3, CH2CH2OH, or CH2CH2NH2 and R9 is OH, NH2, NHCH3, N(CH3)2, OCH3, NHCH3. Note, in the above representation, the methylene carbons may be branched; for example:
-
- Starting material 1 is conveniently prepared from 4-allylazetidinone according to the following scheme:
-
- It should be noted that starting material la is known. Further, in this regard, co-pending, commonly assigned U.S. Patent Application Serial Number 59,842 filed 7/23/79, is incorporated herein by reference for its definition and utilization of starting material la. R is a removable blocking group such as triorganosilyl, for example, trimethylsilyl, t-butyldimethylsilyl, triphenylsilyl, and the like.
- In words relative to the above reaction diagram starting material la can be mono-, or dialkylated at ring position 3. Alkylation of la provides b. Typically, la is treated with a strong base such as lithium diisopropylamide, lithium 2,2,6,6-tetramethylpiperidide, potassium hydride, lithium hexamethyldisilazane, phenyllithium or the like in a solvent such as tetrahydrofuran (THF), hexamethylphosphoramide, ether, dimethoxyethane, and the like at a temperature of from -80°C to 0°C whereupon the alkylating agent of choice, R6X° is added (X° is chloro, iodo or bromo); alternatively the alkylating agent may be R6-tosylate, R 6-mesylate or an aldehyde or ketone such as acetaldehyde to provide monoalkylated species lb. When desired, dialkylated species 1 may be obtained from 1b by repeating the alkylating procedures 1a→1b. The 6-substituents can also be established by direct acylation using an acylating agent such as N-acyl imidazole or the like. Such N-acyl imidazole acylating reagents are listed below. Also given below is a detailed description of this second approach for establishing, R6 and R7. The following list is representative of useful alkylating agents for establishing R6 and R 7, according to the above scheme: 1a→1b→1: Alkylating Agents
- As mentioned above, the 6-substituents may also be established by acylation. Utilization of such acylating agents may be demonstrated in the following manner with regard to a preferred starting material 1:
- The alkylation 1a→1, Scheme II, is accomplished as previously described, by treating 1a in a solvent such as tetrahydrofuran, dimethoxyethane, diethylether, hexamethylphosphoramide, at a temperature of from -100° to -20°C with a strong base such as lithium diisopropylamide, lithium hexamethyldisilazide, lithium 2,2,6,6-tetramethylpiperidide, potassium hydride or the like followed by the addition of an equivalent to 10 fold excess of an aldehyde. This reaction gives a mixture of isomers from which the desired trans-R form 1 can be conveniently separated by chromatography or crystallization.
- Intermediate la may proceed directly to 1 as indicated above, or it may take the circuitous path via 1'. The direct acylation, to 1' is accomplished by treating 1a with two or more equivalents of a base such as lithium diisopropylamide, lithium hexamethyldisilazide, lithium 2,2,6,6-tetramethylpiperidide, in a solvent such as tetrahydrofuran, diethylether, or dimethoxyethane, for example, at a temperature of from -100 to -20°C with an acylating agent such as N-acyl imidazole or the like. Addition of the-la plus base mixture to the acylating agent is preferred.
-
- Further with respect to Scheme II, the reduction, 1'→1 is accomplished by contacting the ketone with a reducing agent such as potassium tri(sec-butyl)borohydride, lithium tri(sec-butyl)borohydride, sodium bprohydride, sodium tris(methoxyethoxy)aluminum hydride, lithium aluminum hydride or the like in a solvent such as diethylether, tetrahydrofuran, toluene or the like at a temperature of from -78° to 25°C. The reaction can conveniently be conducted in the presence of an added complexing salt such as potassium iodide, magnesium bromide or the like.
-
- The oxidation is accomplished with an oxidizing agent such as dipyridine chromium (VI) oxide, trifluoroacetic anhydride-dimethylsulfoxide-triethylamine, pyridinium dichromate, acetic anhydride-dimethylsulfoxide in a solvent such as methylene chloride, acetonitrile, or the like at a temperature of from -78 to 25°C for from 5 minutes to 5 hours.
- As noted above, the compounds of the present invention may also generally be represented by the following structural formula:
- In the generic representation of the compounds of the present invention (I, above), the radical represented by -COX'R3' .is, inter alia, -COOH (X' is oxygen and R3' is hydrogen) and all radicals known to be effective as pharmaceutically acceptable ester, anhydride (R3' is acyl) and amide radicals in the bicyclic β-lactam antibiotic art, such as the cephalosporins and penicillins and nuclear analogues thereof.
- Suitable blocking esters [R3', X' = O) include those selected from the following list which is representative:
- (i) R3' = CRaRbRc wherein at least one of Ra, Rand Rc is an electron-donor, e.g., p-methoxyphenyl. The re- maining R a, Rb and Rc groups may be hydrogen or organic substituting groups. Suitable ester groups of this type include p-methoxybenzyloyxcarbonyl.
- (ii) R3' = CRaRbRc wherein at least one of Ra, Rb and Rc is an electron-attracting group, e.g., p-nitrophenyl, trichloromethyl, and o-nitrophenyl. Suitable esters of this type include p-nitrobenzyloxycarbonyl, and 2,2,2-trichloroethoxycarbonyl.
- (iii) R3' = CRaRbRc wherein at least two of Ra, R b and Rc are hydrocarbon such as alkyl, e.g., methyl or ethyl, or aryl, e.g., phenyl and the remaining Ra, Rb and Rc group, if there is one, is hydrogen. Suitable esters of this type include t-butyloxycarbonyl, diphenylmethoxycarbonyl and triphenylmethoxycarbonyl.
- Silyl esters, under this category of blocking groups, may conveniently be prepared from a halosilane of the formula: R4 3SiX' wherein X' is a halogen such as chloro or bromo and R is alkyl, e.g., methyl,-ethyl, t-butyl.
- Pharmaceutically acceptable carboxyl derivatives of the present invention are those derived by reacting I with alcohols, acylating reagents and the like. For example, esters and amides of interest are the above-listed starting materials and final products having the -COX'R3' group at the 3-position; wherein X' is oxygen, sulfur or NR' (R' is H or R3'), and R31 is alkyl having 1-6 carbon atoms, straight or branched, such as methyl, ethyl, t-butyl, and the like; carbonylmethyl, including phenacyl; aminoalkyl including 2-methylaminoethyl, 2-diethylaminoethyl; alkanoyloxyalkyl wherein the alkanoyloxy portion is straight or branched and has 1-6 carbon atoms and the alkylportion has 1-6 carbon atoms, such as pivaloyloxymethyl; haloalkyl wherein halo is chloro, and the alkyl portion is straight or branched having 1-6 carbon atoms, e.g., 2,2, 2-trichloroethyl; alkenyl having 1-4 carbon atoms such, as 2-propenyl, 3-butenyl, and 4-butenyl; aralkyl and lower.alkoxyl- and nitro- substituted aralkyl such as benzyl, benzhydryl, o-nitrobenzyl, p-methoxybenzyl, and p-nitrobenzyl; phthalidyl; benzyloxyalkyl having 8-10 carbon atoms such as benzyloxymethyl, and (4-nitro) benzyloxymethyl.
- In addition to the esters (and thio esters) listed above, amides are also embraced by the present invention, i.e., wherein X' is the -N- group. Representative of such amides are those wherein R' is selected from the group consisting of hydrogen and lower alkyl such as methyl and ethyl.
- The most preferred -COX' R3' radicals of the present invention are those wherein (relative to Structure I above), X' is oxygen and R3' is hydrogen; loweralkyl having 1-4 carbon atoms; lower alkenyl such as 3-methylbutenyl, 4-butenyl and the like; benzyl and substituted benzyl such as p-nitrobenzyl; pivaloyloxymethyl, 3-phthalidyl; and phenacyl.
- The compounds of the present invention (I) are valuable antibiotics active against various gram-positive and gram-negative bacteria and accordingly.find utility in human and veterinary medicine. Representative pathogens which are sensitive to antibiotics I include: Staphyloccus aureus, Escherichia coli, Klebsiella pneumoniae, Bacillus subtilis, Salmonella typhosa, psuedomonas and Bacterium proteus. The antibacterials of the invention are not limited to utility as medicaments; they may be used in all manner of industry, for example: additives to animal feed, preservation of food, disinfectants, and in other industrial systems where control of bacterial growth is desired. For example, they may be employed in aqueous compositions in concentrations ranging from 0.1 to 100 parts of antibiotic per million parts of solution in order to destroy and inhibit the growth of harmful bacteria on medical and dental equipment and as bactericides in industrial applications, for example in waterbased paints and in the white water of paper mills to inhibit the growth of harmful bacteria.
- The products of this invention may be used in any of a variety of pharmaceutical preparations. They may be employed in capsule, powder form, in liquid solution, or in suspension. They may be administered by a variety of means; those of principal interest include: orally, topically or parenterally by injection (intravenously or intramuscularly).
- Such tablets and capsules, designed for oral administration, may be in unit dosage form, and.may contain conventional excipients, such as binding agents, for example, syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example, lactose, sugar, cornstarch, calcium phosphate, sorbitol, or glycerine; lubricants, for example, magnesium stearate, talc, polyethylene glycol, silica; disintegrants, for example, potato starch; or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in the art. Oral liquid preparations may be in the form of aqueous or oily suspensions, or solutions, or they may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example, sorbitol, methyl cellulose, glucose/sugar syrup, gelatin,- hydroxyethylcellulose, or carboxymethyl cellulose. Suppositories will contain conventional suppository bases, such as cocoa butter or other glycerides.
- Compositions for injection, the preferred route of delivery, may be prepared in unit dosage form in ampules, cr in multidose containers. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous-vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for reconstitution, at the time of delivery, with a suitable vehicle, such as sterile water.
- -The compositions may also be prepared in suitable forms for absorption through the mucous membranes of the nose and throat or bronchial tissues and may conveniently take the form of liquid sprays or inhalants, lozenges, or throat paints. For medication of the eyes or ears, the preparation may be presented in liquid or semi-solid form. Topical applications may be formulated in hydrophobic or hydrophilic bases as ointments, creams, lotions, paints, or powders.
- The dosage to be administered depends to a large extent upon the condition and size of the subject being treated as well as.the route and frequency of administration -- the parenteral route by injection being preferred for generalized infections. Such matters, however, are left to the routine discretion of the therapist according to principles df treatment well known in the antibiotic art. In general, a daily dosage consists of from about 5 to about 600 mg of active ingredient per kg. of body weight of the subject in one or more treatments per day. A preferred daily dosage for adult humans lies in the range of from about 10 to 240 mg. of active ingredient per kg. of body weight. Another factor influencing the precise dosage regimen, apart from the nature-of the infection and peculiar identity of the individual being treated, is the molecular weight of the chosen species of this invention (I).
- The compositions for human delivery per unit dosage, whether liquid or solid, may contain from 0.1% to 99% of active material, the preferred range being from about 10-60%. The composition will generally contain from about 15 mg. to about 1500 mg. of the active ingredient; however, in general, it is preferable to employ a dosage amount in the range of from about 250 mg to 1000 mg. In parenteral administration, the unit dosage is usually the pure compound I in sterile water solution or in the form of a soluble powder intended for solution. For zwitterionic species described under Structure I, the pH of such solutions typically will correspond to the zwitterionic point; however, consideration of individual properties of solubility and stability may require such aqueous solutions to have a pH other than that of the zwitterionic point, for example in the range of 5.5 to 8.2.
- In the foregoing word description of the above schematic reaction diagram for the total synthesis of the defined carbapenem antibiotics, it is to be understood that there is considerable latitude in selection of precise reaction parameters. Suggestion of this latitude and its breadth is generally indicated by the enumeration of equivalent solvent systems, temperature ranges, protecting groups, and range of identities of involved reagents. Further, it is to be understood that the presentation of the synthetic scheme as comprising distinct steps in a given sequence is more in the nature of a descriptive convenience than as a necessary requirement; for one will recognize that the mechanically dissected scheme represents a unified scheme of synthesis and that certain steps, in actual practice, are capable of being merged, conducted simultaneously, or effected in a reverse sequence without materially altering the progress of synthesis.
- The following examples recite a precise scheme of total synthesis. It is to be understood that the purpose of this recitation is to further illustrate the total synthesis and not to impose any limitation. Temperature is given in °C.
-
-
- IR (CHCl3) 3400, 2920, 2850, 1723 cm-1; n.m.r. (CDCl3 + D2O) δ 4.9-6.2 (3H, m, olefinic) ,δ 4.1 (lH, dq, J= 7.0, 6.8, H8), δ 3.66 (lH, ddd, J= 11, 4.5, 3.0, H5), δ 2.9 (1H, dd, J=6.8, 3.0, H6)δ 1.8-2.8 (2H, m, allyl ), δ 1.26 (3H, d, J=7.0, CH3-) , δ 1.0 (9H, S, ± Si) , δ 0.28 (6H, 2S, (CH3)2Si).
-
- B. n-Butyllithium in hexane (4.10 mmol) is added by syringe to a solution of diisopropylamine (4.10 mmol) in anhydrous tetrahydrofuran (16 ml) at -78°C. The resulting solution is stirred at -78°C for 15 min. prior to the addition of a solution of l-(t-butyldimethylsilyl)-4-(prop-2-ene)-azetidin-2-one (2.0 mmol) in anhydrous tetrahydrofuran (2 ml). After an additional 15 min. at -78°C, the reaction mixture is added via a Teflon tube to a mixture of N-acetylimidazole (4.1 mmol) in anhydrous tetrahydrofuran (16 ml) at -78°C. The resulting yellow reaction mixture is stirred at -78°C for 15 min, then quenched by addition of saturated aqueous ammonium chloride solution (10 ml). The reaction mixture is diluted with ether (100 ml) and washed with 2.5N hydrochloric acid solution (25 ml) water (25 ml) and brine. The organic phase is dried over magnesium sulfate and concentrated in vacuo to yield an oil. This material is chromatographed on silica gel (2:1 petroleum ether:ether) to yield (3S*,4R*)-1-(t-butyldimethylsilyl) -3- (1-oxoethyl) -4- (prop-2-ene) - azetidin-2-one.
-
-
-
-
-
-
-
-
-
-
- NMR of 3α methyl component (300MHz, CDCl3)δ 0.24 and 0.26 (2S, Si(CH3)2), 0.97 (S, Si-C(CH3)3), 1.22 (d, J=6Hz, CH3CHOH-), 1.30 (S, CH3), 2.34 (d, OH), 2.42-2.81 (m, CH2CH=CH2), 3.44 (dd, J=4 and 10Hg, H4), 4.09 - 4.19 (m, CH3CHOH-), 5.09-6.02 (m, -CH=CH2).
- NMR of 3β-methyl components (300MHz, CDCl3)δ 0.23-0.25 (s's, Si(CH3)2'S), 0.95 and 0.96(2S, Si-C(CH3)3'S), 1.14 - 1.22 (series of peaks for CH3's and CH3CHOH'S) 2.29 - 2.62 (m, CH2CH=CH2), 3.40 (dd, J=3.5 and llHz, H4 of S *), 3.70 (dd, J=3.5 and 11 Hz, H4 of R*), 3.86 - 4.00 (m, CH3CHOH-), 5.08-5.96 (m, CH-CH2).
-
-
-
-
-
-
-
- Data for the compound: IR(CHCl3)µ 5.70(br), 5.81(sh) M.S. m/e NMR(300MHz, CDCl3)δ 1.14 (s, CH3), 1.23 (d, J=6Hz, CH3CHOH), 2.81-2.98 (m, CH2CH2CO2-) , 3.62 (s, CH2CO2-CH2φPNO2), 4.05(center of m, H4 and CH3CHOH), 5.30 (s, CO2CH2φpNO2), 6.01(br, s, NH), 7.57 and 8.30 (2d, aromatics).
-
-
-
- The combined aqueous solutions are concentrated in vacuo without heat to 3 ml volume. The solution is passed portionwise through a semi-prep (9.5ml void volume) µ-Bondapak-C18 HPLC column (3% THF/DI-H20, flow rate-2 ml/min, 254mµ filter), and the major peak is collected. Concentration, as above, afforded a soltuion of 2.1mg of the title compound having a hydroxylamine-quenchable UVmax at 297mµ, essentially no electrophoretics mobility in pH7 phosphate buffer (1500V-30 min), and a clean HPLC trace (retention time ~ 6.5 min).
-
-
- The final antibiotic compounds of the present invention Structure I:
- The compounds of the present invention may also be prepared by the processes disclosed and claimed in the three (3) following, co-pending, commonly assigned U.S. Patent Applications of Christensen, Ratcliffe and Salzmann. To the extent that these applications define R6, R7, and R8 of Structure I and to the extent that they describe processes for the synthesis of intermediates III and IV (defined above) they are hereby incorporated by reference.
- 1.) Process for the Preparation of 1-Carbapenems and Intermediates via 4-Allylazetidinone; U.S. Patent Application Serial Number , filed 3-27-80 [Merck & Co., Inc. Attorney's Docket Case 16479].
- 2.) Process for the Preparation of 1-Carbapenems and Intermediates via Trithioorthoacetates; U.S. Patent Application Serail Number , filed 3-27-80 [Merck & Co., Inc. Attorney's Docket Case 16485].
- 3.) Process for the Preparation of 1-Carbapenems and Intermediates via Silyl-Substituted Dithioacetals; U.S. Patent Application Serial Number filed 3-27-80 [Merck & Co., Inc. Attorney's Docket Case 16478].
- Also incorporated by reference is published European Patent Application 0007614 (Application Number 79102615.6, filed 24 July 1979). This application discloses certain dipeptidase inhibitors which, on co-administration to mammalian subjects, enhance the efficacy of certain 1-carbadethiapenem antibiotics. Thus, to the extent that the cited application: l.)defines the manner by which susceptible carbadethiapenems substrates of the present invention may be identified; and 2.) discloses suitable inhibitors, compositions, and methods of treatment, it is incorporated herein by reference. A particularly preferred inhibitor is 6-(L-2-Amino-2-carboxyethylthio)-2-(2,2-DCC)-2-hexenoic acid.
- Intermediates IV wherein X is halo are conveniently prepared from intermediates III by the procedures disclosed in co-pending, commonly assigned U.S. Patent Application Serial Number 26,979 filed April 4, 1979, which is incorporated herein by reference.
Claims (19)
1. A process for preparing a compound having the structural formula:
and the pharmaceuticaliy acceptable salt ester and amide derivatives thereof; wherein R6, R and R8 are independently selected from the group consisting of: hydrogen; substituted and unsubstituted: alkyl, alkenyl, and alkynyl, having from 1-10 carbon atoms; cycloalkyl, cycloalkylalkyl, and alkylcycloalkyl, having 3-6 carbon atoms in the cycloalkyl ring and 1-6 carbon atoms in the alkyl moieties; phenyl, aralkyl, aralkenyl, and aralkynyl wherein the aryl moiety is phenyl and the aliphatic portion has 1-6 carbon atoms; heteroaryl, heteroaralkyl, heterocyclyl and heterocyclylalkyl; wherein the substituent or substituents relative to the above-named radicals are selected from the group consisting of: chloro, bromo, fluoro, R 1,
wherein, relative to the above listed substituents on R6, R7 and R8, the groups R1 and R2 are independently selected from: hydrogen, alkyl, alkenyl, and alkynyl, having from 1-10 carbon atoms; cycloalkyl, cycloalkylalkyl, and alkylcycloalkyl, having 3-6 carbon atoms in the cycloalkyl ring and 1-6 carbon atoms in the alkyl moieties; phenyl; aralkyl, aralkenyl, and aralkynyl wherein the aryl moiety is phenyl and the aliphatic portion has 1-6 carbon atoms; heteroaryl, heteroaralkyl, heterocyclyl and heterocyclylalkyl; and wherein the hetero atom or atoms in the above-named heterocyclic moieties are selected from the group consisting of 1-4 oxygen, nitrogen or sulphur atoms and wherein the alkyl moieties associated with said heterocyclic moieties have 1-6 carbon atoms; comprising activating and treating with HSR8 a compound of the structure:
wherein R3 is a protecting group or a pharmaceutically acceptable ester moiety; when R6/R7 is hydrogen and R7/R6 is CH3CH(OH), then R8 is not -CH2CH2NH2.
3. A compound selected from:
wherein X is a leaving group, R3 is hydrogen, a salt cation, a protecting group, or a pharmaceutically acceptable ester moiety; and wherein R6, R 7 and R8 are independently selected from the group consisting of: hydrogen; substituted and unsubstituted: alkyl, alkenyl, and alkynyl, having from 1-10 carbon atoms; cycloalkyl, cycloalkylalkyl, and alkylcycloalkyl, having 3-6 carbon atoms in the cycloalkyl ring and 1-6 carbon atoms in the alkyl moieties; phenyl, aralkyl, aralkenyl, and aralkynyl wherein the aryl moiety is phenyl and the aliphatic portion has 1-6 carbon atoms; heteroaryl, heteroaralkyl, heterocyclyl and heterocyclylalkyl; wherein the substituent or substituents relative to the above-named radicals are selected from the group consisting of: chloro, bromo, fluoro, R1,
wherein, relative to the above listed substituents on R 6, R and R8, the groups R1 and R2 are independently selected from: hydrogen, alkyl, alkenyl, and alkynyl, having from 1-10 carbon atoms; cycloalkyl, cycloalkylalkyl, and alkylcycloalkyl, having 3-6 carbon atoms in the cycloalkyl ring and 1-6 carbon atoms in the alkyl moieties; phenyl; aralkyl, aralkenyl, and aralkynyl wherein the aryl moiety is phenyl and the aliphatic portion has 1-6 carbon atoms; heteroaryl, heteroaralkyl, heterocyclyl and heterocyclylalkyl; and wherein the hetero atom or atoms in the above-named heterocyclic moieties are selected from the group consisting of 1-4 oxygen, nitrogen or sulphur atoms and wherein the alkyl moieties associated with said heterocyclic moieties have 1-6 carbon atoms; when R6/R7 is hydrogen, then R7/R6 is not CH3CH(OH).
4. A compound according to Claim 3, wherein R7 is selected from H, OCH3 and CH3.
5. A compound according to Claim 4 wherein R6 is selected from the group consisting of: substituted and unsubstituted: alkyl, alkenyl and cycloalkylalkyl wherein the substituent or substituents are selected from hydroxyl, alkoxyl having from 1-6 carbon atoms, phenoxy, amino, and carboxy.
6. A compound according to Claims 4 or 5 wherein R6 is selected from the group consisting of alkyl, cycloalkylalkyl, alkyl substituted by one or more hydroxyl groups, or cycloalkylalkyl substituted by one or more hydroxyl groups.
7. A compound according to Claims 4, 5 or 6 wherein R7 is hydrogen.
9. A compound according to Claim 3 wherein X is chloro, bromo, iodo, phenylsulfonyloxy, p-toluylsulfonyloxy, p-nitrophenylsulfonyloxy, methylsulfonyloxy, trifluoromethylsulfonyloxy, diphenylphosphoryl, bis(trichloroethyl)phosphoryl.
10. A compound according to Claims 3, 4 or 7 selected from: H,
wherein: y = 0 or 1; X = OH, NH2; SH; n 0 or 1; R = substituted or unsubstituted: alkyl, alkenyl or alkynyl having 1-6 carbon atoms wherein the substituent is R1; R1° = alkoxyl, carboxyl, CF3, OH, H, linear or branched alkyl bearing 1 or more hydroxyl groups, amino, aminoalkyl, Cl, F, Br, alkylthio, amidino, guanidino, oximino, phenyloxy, phenylthio,
11. A process according to Claims 1 or 2 wherein R8 is selected from:
1.) aliphatic (including carbocyclic) groups having 1-10 carbon atoms selected from: alkyl, cycloalkyl, alkenyl, cycloalkenyl and alkynyl;
2.) substituted aliphatic groups having 1-10 carbon atoms selected from: alkyl, cycloalkyl, alkenyl, cycloalkenyl and alkynyl; wherein the substituents are selected from: chloro, bromo, fluoro, R1,
3.) aryl and substituted aryl; wherein the aryl is phenyl and wherein the substituents are defined above under 2.);
4.) heteroaryl and substituted heteroaryl having 1-4 O, N or S atoms; and wherein the substituents are defined above under 2.);
5.) arylaliphatic, wherein aryl is phenyl, which are selected from the aliphatic groups defined under 1.) which are substituted by phenyl or substituted phenyl; wherein such substituents on phenyl are defined under 2.), above;
6.) heteroarylaliphatic and heterocyclylaliphatic; wherein the aliphatic moiety is defined under 1.), above; the substituted and unsubstituted heteroaryl and heterocyclic moieties have 1-4 O, N or S atoms; wherein such substituents are defined under 2.),above;
7.) substituted and unsubstituted alkyl-heteroatom-alkyl having 4-12 carbon atoms; wherein the heteroatom is selected from: O, S, NR° (R° is H, substituted or unsubstituted alkyl); wherein such substituents are defined under 2.),above.
13. A process according to Claim 11, subparagraph 2.); wherein R8 is selected from:
n = 2-6; R1 = H,
n=1-6; X=O, NH, NR1, R1=H, CH3
n-2-6
n=2-6; R1=CH3, CH2CH3, CH2CH2CH3,
n=2-6; R1/R2=CH3, CH2CH3; CH3,CH3; CH2CH3,CH2CH3
R1=H, CH3,
n-3-5
R1 and R2 are independently chosen from H and CH3
n=1, R2/R1=H,H; CH3,H
17. A process according to Claim 11, sub paragraph 6.); wherein R8 is:
R1 = OCH2CH3
X = O, S, NH
X = O, S, NH
X = O, S, NH
X = O, S, NH
X = O, S, NH
R1=H, CH3
m = 1-3 n = 1-3
R2=H, CH3, R1=H, CH3, NH2
R1= H, CH3
R1=H, CH3
X = O, S, NH
R1 = H, CH3 R1 = H, CH3
R1 = H, CH3
X = O, NH, NCH3
R1 = H, CH3
R1 = H, CH3
R1 = H, CH3
R1 = H, CH3
R1 = H, CH3
X = 0, S, NH
X = O, S, NH
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP80102338A EP0038869A1 (en) | 1980-04-30 | 1980-04-30 | Process for the preparation of 1-carbapenems, and intermediates for their preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP80102338A EP0038869A1 (en) | 1980-04-30 | 1980-04-30 | Process for the preparation of 1-carbapenems, and intermediates for their preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0038869A1 true EP0038869A1 (en) | 1981-11-04 |
Family
ID=8186674
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP80102338A Ceased EP0038869A1 (en) | 1980-04-30 | 1980-04-30 | Process for the preparation of 1-carbapenems, and intermediates for their preparation |
Country Status (1)
Country | Link |
---|---|
EP (1) | EP0038869A1 (en) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0071908A1 (en) * | 1981-08-03 | 1983-02-16 | Merck & Co. Inc. | 1-, and 1,1-disubstituted-6-substituted-2-carbamimidoyl-1-carbadethiapen-2-em-3-carboxylic acids, a process for preparing and an antibiotic composition containing the same |
EP0072710A1 (en) * | 1981-08-19 | 1983-02-23 | Sankyo Company Limited | Carbapenem derivatives, their preparation and compositions containing them |
FR2524890A1 (en) * | 1982-04-09 | 1983-10-14 | Bristol Myers Co | NOVEL CARBAPENEM DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, INTERMEDIATE COMPOUNDS FOR THEIR PREPARATION, AND PROCESSES FOR THEIR PRODUCTION |
FR2524888A1 (en) * | 1982-04-08 | 1983-10-14 | Bristol Myers Co | NEW ANTIBIOTICS OF CARBAPENEM TYPE |
DE3334937A1 (en) * | 1982-09-28 | 1984-04-05 | Bristol-Myers Co., 10154 New York, N.Y. | CARBAPENEM DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS |
FR2542316A1 (en) * | 1983-03-08 | 1984-09-14 | Bristol Myers Co | PROCESS FOR THE PREPARATION OF CARBAPENEM DERIVATIVES, NOVEL INTERMEDIATES FOR SYNTHESIS AND PROCESS FOR THE PREPARATION OF SUCH INTERMEDIATES |
DE3390137T1 (en) * | 1982-07-26 | 1984-09-20 | Sandoz-Patent-GmbH, 7850 Lörrach | Fluoroalkylated carbapenem derivatives |
EP0126780A1 (en) * | 1983-04-12 | 1984-12-05 | Schering Corporation | Carbapenem compound |
US4536335A (en) * | 1982-06-18 | 1985-08-20 | Bristol-Myers Company | Carbapenem antibiotics |
US4640799A (en) * | 1982-06-18 | 1987-02-03 | Bristol-Myers Company | Carbapenem antibiotics |
US4642341A (en) * | 1982-04-09 | 1987-02-10 | Bristol-Myers Company | Carbapenem antibiotics |
US4665169A (en) * | 1985-09-11 | 1987-05-12 | Bristol-Myers Company | Carbapenem antibiotics |
US4665170A (en) * | 1982-06-18 | 1987-05-12 | Bristol-Myers Company | Carbapenem antibiotics |
US4683301A (en) * | 1982-04-08 | 1987-07-28 | Bristol-Myers Company | Carbapenem antibiotics |
EP0235823A2 (en) | 1986-03-06 | 1987-09-09 | Bristol-Myers Squibb Company | Carbapenem antibiotics, a process for preparing them and pharmaceutical compositions containing them |
US4710568A (en) * | 1982-04-09 | 1987-12-01 | Bristol-Myers Company | Carbapenem antibiotics |
US4732977A (en) * | 1982-09-28 | 1988-03-22 | Bristol Myers Company | Carbapenem antibiotics |
US4746736A (en) * | 1982-09-28 | 1988-05-24 | Bristol-Myers Company | Carbapenem antibiotics |
EP0757051A1 (en) * | 1995-02-17 | 1997-02-05 | Suntory Limited | Penem derivatives and antimicrobial agent containing the same |
WO1997025325A1 (en) * | 1996-01-12 | 1997-07-17 | Takeda Chemical Industries, Ltd. | Carbapenem compounds, their production and use |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0007973A1 (en) * | 1978-08-14 | 1980-02-20 | Merck & Co. Inc. | Process for the preparation of thienamycin and intermediates |
EP0017970A1 (en) * | 1979-04-17 | 1980-10-29 | Sanraku-Ocean Co., Ltd. | Novel beta-lactam derivatives and process for production thereof |
-
1980
- 1980-04-30 EP EP80102338A patent/EP0038869A1/en not_active Ceased
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0007973A1 (en) * | 1978-08-14 | 1980-02-20 | Merck & Co. Inc. | Process for the preparation of thienamycin and intermediates |
EP0017970A1 (en) * | 1979-04-17 | 1980-10-29 | Sanraku-Ocean Co., Ltd. | Novel beta-lactam derivatives and process for production thereof |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0071908A1 (en) * | 1981-08-03 | 1983-02-16 | Merck & Co. Inc. | 1-, and 1,1-disubstituted-6-substituted-2-carbamimidoyl-1-carbadethiapen-2-em-3-carboxylic acids, a process for preparing and an antibiotic composition containing the same |
GB2163156A (en) * | 1981-08-19 | 1986-02-19 | Sankyo Co | Carbapenem derivatives, their preparation and compositions containing them |
FR2511678A1 (en) * | 1981-08-19 | 1983-02-25 | Sankyo Co | CARBAPENEMIC DERIVATIVES, PROCESS FOR PREPARING THEM AND THEIR THERAPEUTIC APPLICATION |
US4552873A (en) * | 1981-08-19 | 1985-11-12 | Sankyo Company Limited | Carbapenem compounds, and compositions containing them |
EP0165384A1 (en) * | 1981-08-19 | 1985-12-27 | Sankyo Company Limited | Carbapenem derivatives, their preparation and compositions containing them |
EP0072710A1 (en) * | 1981-08-19 | 1983-02-23 | Sankyo Company Limited | Carbapenem derivatives, their preparation and compositions containing them |
USRE34960E (en) * | 1981-08-19 | 1995-05-30 | Sankyo Company, Limited | Carbapenem compounds, and compositions containing them |
US4683301A (en) * | 1982-04-08 | 1987-07-28 | Bristol-Myers Company | Carbapenem antibiotics |
FR2524888A1 (en) * | 1982-04-08 | 1983-10-14 | Bristol Myers Co | NEW ANTIBIOTICS OF CARBAPENEM TYPE |
FR2524890A1 (en) * | 1982-04-09 | 1983-10-14 | Bristol Myers Co | NOVEL CARBAPENEM DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, INTERMEDIATE COMPOUNDS FOR THEIR PREPARATION, AND PROCESSES FOR THEIR PRODUCTION |
US4710568A (en) * | 1982-04-09 | 1987-12-01 | Bristol-Myers Company | Carbapenem antibiotics |
US4642341A (en) * | 1982-04-09 | 1987-02-10 | Bristol-Myers Company | Carbapenem antibiotics |
US4640799A (en) * | 1982-06-18 | 1987-02-03 | Bristol-Myers Company | Carbapenem antibiotics |
US4665170A (en) * | 1982-06-18 | 1987-05-12 | Bristol-Myers Company | Carbapenem antibiotics |
US4536335A (en) * | 1982-06-18 | 1985-08-20 | Bristol-Myers Company | Carbapenem antibiotics |
DE3390137T1 (en) * | 1982-07-26 | 1984-09-20 | Sandoz-Patent-GmbH, 7850 Lörrach | Fluoroalkylated carbapenem derivatives |
US4732977A (en) * | 1982-09-28 | 1988-03-22 | Bristol Myers Company | Carbapenem antibiotics |
US4746736A (en) * | 1982-09-28 | 1988-05-24 | Bristol-Myers Company | Carbapenem antibiotics |
DE3334937A1 (en) * | 1982-09-28 | 1984-04-05 | Bristol-Myers Co., 10154 New York, N.Y. | CARBAPENEM DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS |
FR2542316A1 (en) * | 1983-03-08 | 1984-09-14 | Bristol Myers Co | PROCESS FOR THE PREPARATION OF CARBAPENEM DERIVATIVES, NOVEL INTERMEDIATES FOR SYNTHESIS AND PROCESS FOR THE PREPARATION OF SUCH INTERMEDIATES |
EP0126780A1 (en) * | 1983-04-12 | 1984-12-05 | Schering Corporation | Carbapenem compound |
US4665169A (en) * | 1985-09-11 | 1987-05-12 | Bristol-Myers Company | Carbapenem antibiotics |
EP0235823A2 (en) | 1986-03-06 | 1987-09-09 | Bristol-Myers Squibb Company | Carbapenem antibiotics, a process for preparing them and pharmaceutical compositions containing them |
EP0757051A1 (en) * | 1995-02-17 | 1997-02-05 | Suntory Limited | Penem derivatives and antimicrobial agent containing the same |
EP0757051A4 (en) * | 1995-02-17 | 1997-05-28 | Suntory Ltd | Penem derivatives and antimicrobial agent containing the same |
WO1997025325A1 (en) * | 1996-01-12 | 1997-07-17 | Takeda Chemical Industries, Ltd. | Carbapenem compounds, their production and use |
US6174877B1 (en) | 1996-01-12 | 2001-01-16 | Takeda Chemical Industries, Ltd. | Carbapenem compound, their production and use |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0037080B1 (en) | 4-(3-carboxy-2-oxopropyl)-azetidino-2-ones and process for their preparation | |
EP0001628B1 (en) | 3-substituted-6-substituted-7-oxo-1-azabicyclo (3.2.0)-hept-2-ene-2-carboxylic acid, its preparation and pharmaceutical compositions containing it | |
EP0071908B1 (en) | 1-, and 1,1-disubstituted-6-substituted-2-carbamimidoyl-1-carbadethiapen-2-em-3-carboxylic acids, a process for preparing and an antibiotic composition containing the same | |
US4383946A (en) | Process for the preparation of 1-carbapenems and intermediates via silyl-substituted dithioacetals | |
US4312871A (en) | 6-, 1- And 2-substituted-1-carbadethiapen-2-em-3-carboxylic acids | |
EP0037081A1 (en) | Process for the preparation of 1-carbapenems and intermediates via trithioorthoacetates | |
EP0017992A1 (en) | 2-Substituted-6-substituted-1-carbadethiapen-2-em-3-carboxylic acids, processes for preparing them, antibiotic pharmaceutical compositions containing same and process for preparing intermediates | |
EP0038869A1 (en) | Process for the preparation of 1-carbapenems, and intermediates for their preparation | |
US4350631A (en) | 6- and 4-Substituted-1-azabicyclo[3.2.0]heptan-3,7-dione-2-carboxylates | |
EP0001627B1 (en) | 3-substituted-6-(1'hydroxethyl)-7-oxo-1-azabicyclo(3.2.0.)-hept-2-ene-2-carboxylic acid, its preparation and pharmaceutical compositions containing it | |
US4217453A (en) | 6-Amido-3-substituted-amino-1-azabicyclo[3.2.0]hept-2-en-7-one-2-carboxylic acid | |
US4318912A (en) | 6-(1-Hydroxyethyl)-3-substituted-1-azabicyclo(3.2.0)-hept-2-en-7-one-2-carboxylic acid | |
US4262010A (en) | 6-(1-Hydroxyethyl)-2-(2-aminoethylthio)-1,1-disubstituted-1-carbadethiapen-2-em-3-carboxylic acids | |
EP0037082B1 (en) | Process for the preparation of 1-carbapenems and intermediates via silyl-substituted dithioacetals | |
US4218463A (en) | 3-Substituted thio-6-amido-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | |
US4262009A (en) | 6- And 1,1-disubstituted-1-carbadethiapen-2-em-3-carboxylic acid | |
US5459260A (en) | Tricyclic or tetracyclic carbapenem compounds, their production and use | |
EP0074599A1 (en) | 5,6-cis-Carbapenem derivatives, their production and use | |
US4310538A (en) | 3-Halo-1-azabicyclo[3.2.0]hept-2-en-7-one-2-carboxylic acid | |
EP0030032B1 (en) | 6-, 1- and 2-substituted-1-carbadethiapen-2-em-3-carboxylic acids, processes for preparing the same, pharmaceutical compositions containing the same, and intermediates | |
US4530841A (en) | 6- And 6,6-disubstituted-3-substituted amino-1-azabicyclo-[3.2.0]hept-2-en-7-one-2-carboxylic acid | |
US4347367A (en) | 3-Substituted-6-(1'-hydroxyethyl)-7-oxo-1-azabicyclo[3.2.0]-hept-2-ene-2-carboxylic acid | |
US4224336A (en) | 3-(2-Aminoethylthio)-6-amido-7-oxo-1-azabicyclo[3.2.0]-hept-2-ene-2-carboxylic acid | |
US4347368A (en) | 3-Substituted-6-substituted-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | |
US4298741A (en) | 6-Amido-3-substituted-1-azabicyclo[3.2.0]-hept-2-en-7-one-2-carboxylic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE FR GB IT LU NL SE |
|
ITCL | It: translation for ep claims filed |
Representative=s name: SOCIETA' ITALIANA BREVETTI S.P.A. |
|
17P | Request for examination filed |
Effective date: 19820329 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 19851206 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: RATCLIFFE, RONALD W. Inventor name: CHRISTENSEN, BURTON G. |